CL2024002402A1 - Inhibidores de irak4 - Google Patents

Inhibidores de irak4

Info

Publication number
CL2024002402A1
CL2024002402A1 CL2024002402A CL2024002402A CL2024002402A1 CL 2024002402 A1 CL2024002402 A1 CL 2024002402A1 CL 2024002402 A CL2024002402 A CL 2024002402A CL 2024002402 A CL2024002402 A CL 2024002402A CL 2024002402 A1 CL2024002402 A1 CL 2024002402A1
Authority
CL
Chile
Prior art keywords
irak4 inhibitors
irak4
medicine
consequently
formula
Prior art date
Application number
CL2024002402A
Other languages
English (en)
Inventor
Terstiege Ina
Schiesser Stefan
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CL2024002402A1 publication Critical patent/CL2024002402A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente solicitud se refiere a compuestos químicos de Fórmula (I), y sales farmacéuticamente aceptables de estos, que inhiben IRAK4 y en consecuencia tienen una posible utilidad en medicina.
CL2024002402A 2022-02-14 2024-08-12 Inhibidores de irak4 CL2024002402A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263267956P 2022-02-14 2022-02-14

Publications (1)

Publication Number Publication Date
CL2024002402A1 true CL2024002402A1 (es) 2025-01-17

Family

ID=85227248

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024002402A CL2024002402A1 (es) 2022-02-14 2024-08-12 Inhibidores de irak4

Country Status (18)

Country Link
US (2) US12240832B2 (es)
EP (1) EP4479137A1 (es)
JP (2) JP7555519B2 (es)
KR (1) KR20240051921A (es)
CN (1) CN118591536A (es)
AR (1) AR128506A1 (es)
AU (1) AU2023218575A1 (es)
CA (1) CA3250704A1 (es)
CL (1) CL2024002402A1 (es)
CO (1) CO2024012172A2 (es)
CR (1) CR20240383A (es)
DO (1) DOP2024000148A (es)
IL (1) IL314800A (es)
MX (1) MX2024009843A (es)
PE (1) PE20242100A1 (es)
TW (1) TW202400574A (es)
UY (1) UY40145A (es)
WO (1) WO2023152349A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121773099A (zh) 2023-08-11 2026-03-31 阿斯利康(瑞典)有限公司 结晶irak4抑制剂

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3126330T3 (en) 2014-04-04 2019-04-23 Pfizer BICYCLE-FUSED HETEROARYL OR ARYL COMPOUNDS AND USE THEREOF AS IRAC4 INHIBITORS
TW201701879A (zh) 2015-04-30 2017-01-16 拜耳製藥公司 Ｉｒａｋ４抑制劑組合
CN108024971A (zh) 2015-07-15 2018-05-11 奥列基因发现技术有限公司 作为irak-4抑制剂的取代的氮杂化合物
SG10202011653WA (en) 2016-06-01 2020-12-30 Bayer Pharma AG Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases
EP3642201A1 (en) 2017-06-21 2020-04-29 H. Hoffnabb-La Roche Ag Isoindolinone derivatives as irak4 modulators
JP7576581B2 (ja) 2019-06-27 2024-10-31 バイオジェン・エムエイ・インコーポレイテッド イミダゾ［１，２－ａ］ピリジニル誘導体及び疾患の処置におけるそれらの使用
US20230002361A1 (en) 2019-06-27 2023-01-05 Biogen Ma Inc. 2h-indazole derivatives and their use in the treatment of disease
AU2020352311B2 (en) 2019-09-24 2023-11-09 Wuhan Createrna Science And Technology Co., Ltd. IRAK inhibitor and preparation method therefor and use thereof
US11866405B2 (en) 2020-12-10 2024-01-09 Astrazeneca Ab Substituted indazoles as IRAK4 inhibitors
AR124451A1 (es) * 2020-12-22 2023-03-29 Biogen Ma Inc DERIVADOS DE IMIDAZO[1,2-a]PIRIDINILO Y SU USO EN EL TRATAMIENTO DE ENFERMEDADES
KR20230134499A (ko) 2020-12-22 2023-09-21 바이오젠 엠에이 인코포레이티드 Irak4 억제제로서의 2h-인다졸 유도체 및 질환의 치료에서의그의 용도
EP4367113A1 (en) * 2021-07-07 2024-05-15 Biogen MA Inc. Compounds for targeting degradation of irak4 proteins

Also Published As

Publication number Publication date
MX2024009843A (es) 2024-08-22
US20240300923A1 (en) 2024-09-12
JP2025020096A (ja) 2025-02-12
UY40145A (es) 2023-08-15
TW202400574A (zh) 2024-01-01
JP7555519B2 (ja) 2024-09-24
CR20240383A (es) 2024-11-22
AU2023218575A1 (en) 2024-09-19
JP2024529501A (ja) 2024-08-06
AR128506A1 (es) 2024-05-15
IL314800A (en) 2024-10-01
CN118591536A (zh) 2024-09-03
US20250368613A1 (en) 2025-12-04
DOP2024000148A (es) 2024-09-15
CA3250704A1 (en) 2023-08-17
KR20240051921A (ko) 2024-04-22
WO2023152349A1 (en) 2023-08-17
US12240832B2 (en) 2025-03-04
PE20242100A1 (es) 2024-10-28
CO2024012172A2 (es) 2024-09-30
EP4479137A1 (en) 2024-12-25

Similar Documents

Publication Publication Date Title
UY39561A (es) Inhibidores de IRAK4
CL2024002023A1 (es) Inhibidor del inflamosoma nlrp3 y uso del mismo
MX2025001036A (es) Composicion farmaceutica que comprende un inhibidor de kras g12d
NO20061432L (no) N3 alkylerte benzimidazolederivater som MEK-inhibitorer
ECSP20044709A (es) Inhibidores de sarcómero cardíaco
CO2024003923A2 (es) Uso de un inhibidor de la ezh2 en la preparación de fármacos para el tratamiento del linfoma de linfocitos t
MA33886B1 (fr) Dérivés substitués d'acide carbamoylméthylamino-acétique utilisés comme nouveaux inhibiteurs de nep
CO2024012172A2 (es) Inhibidores de irak4
MA33364B1 (fr) Dérivés aminobutyriques substitués en tant qu'inhibiteurs de néprilysine
MX2012014387A (es) Dispersiones solidas que contienen inhibidores de cinasa.
PE20130396A1 (es) N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolina-3-carboxamida deuterada, sales y usos de la misma
CO2025007341A2 (es) Inhibidor del inflamosoma nlrp3 y uso de este
MX2023006854A (es) Forma cristalina de tolebrutinib, metodo de preparacion y uso de la misma.
AR049578A1 (es) Derivados de hidantoina, procesos de obtencion y composiciones farmaceuticas
PE20110943A1 (es) Formulacion oral solida de alisquireno
CL2022002817A1 (es) Inhibidores de replicación del virus de inmunodeficiencia humana
ECSP22032016A (es) Inhibidor de irak y método de preparación para el mismo y uso del mismo
UY39588A (es) Pirazolotiazol carboxamidas y usos de estas como inhibidores de pdgfr
CO2024000054A2 (es) Forma cristalina de tolebrutinib y método de preparación y su uso
PY2085970A (es) Compuestos químicos
MX2025007935A (es) Nuevos inhibidores reversibles de dpp1 y usos de estos
CO2024010726A2 (es) Compuestos heterocíclicos y métodos de uso
MX2026001703A (es) Preparacion farmaceutica de un derivado de piperazina, metodo de preparacion de la misma y uso de la misma
MX2024004551A (es) Inhibidores de la replicacion del virus de inmunodeficiencia humana.
RU2009132502A (ru) Применение адапалена и пероксида бензоила для продолжительного лечения угрей обыкновенных